Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA
Terminated
M.D. Anderson Cancer Center
Phase 1
2007-05-01
- Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative
radiopharmaceutical for CSF imaging.
- Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and
radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during
remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and
recurrence.
This is a single center cross-sectional imaging study investigating the use of gallium-68
citrate PET in patients with metastatic castration-resistant prostate cancer who are planning
to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519).
The study population will consist of patients with metastatic castration-resistant prostate
cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001
(CC#125519), with evidence of resistance to androgen signaling inhibition.
The study will involve gallium-68 PET scan obtained at single time point, followed by
radiographically-guided metastatic tumor biopsy within 14 days of PET scan.
This is a single center cross-sectional imaging study investigating the use of gallium-68
citrate PET in patients with metastatic castration-resistant prostate cancer who are planning
to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519).
The study population will consist of patients with metastatic castration-resistant prostate
cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001
(CC#125519), with evidence of resistance to androgen signaling inhibition.
The study will involve gallium-68 PET scan obtained at single time point, followed by
radiographically-guided metastatic tumor biopsy within 14 days of PET scan.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
